ZUG, Switzerland - Thursday, 23. July 2026
Ad hoc announcement pursuant to Art. 53 LR
(BUSINESS WIRE)--Galderma Group AG (SIX: GALD), the pure-play dermatology category leader, today announced its financial results for the first half of 2026.
- Net sales reached 3.134 billion USD, surpassing 3 billion USD for the first time in the first six months of the year and representing net sales growth of 24.6% at constant currency1.
- Broad-based, double-digit growth in both International markets and the U.S. as well as in all product categories, primarily driven by volume and complemented by favorable mix.
- Outperforming the market in each product category, with net sales growth year-on-year at constant currency of 12.1% in Injectable Aesthetics, 16.4% in Dermatological Skincare, and 67.9% in Therapeutic Dermatology.
- Demonstrating leadership in dermatology through ongoing geographic expansion and differentiated innovation, including Nemluvio® (nemolizumab), which generated 433 million USD in net sales, Relfydess™ (RelabotulinumtoxinA), which continues to ramp-up with approvals in 33 International markets, alongside continued investment in science-based innovation and medical education.
- Core EBITDA2 margin expansion of 328 basis points at constant currency, ahead of initial expectations for the first half, with Core EBITDA reaching 802 million USD, up 42.8% year-on-year at constant currency, and a Core EBITDA margin of 25.6%.
- Core EPS3 grew to 2.34 USD, up 68.5% year-on-year, driven by strong Core EBITDA and reduced financing costs.
- Raising 2026 full-year net sales guidance to 19-21% growth at constant currency (previously 17-20%) based on a strong trajectory, and confirming Core EBITDA margin of approximately 26% at constant currency.
|
“Galderma delivered a strong
first half of 2026, with broad-based growth across geographies and
product categories, reflecting the strength of our integrated
dermatology strategy. Our upcoming inclusion in the Swiss Market Index,
Switzerland’s leading blue-chip equity index, effective September 21, is
an important milestone in our journey as a listed company and further
recognition of Galderma’s progress. Building on this momentum, we are
raising our full-year net sales growth guidance as we continue to
advance our dermatology powerhouse ambition.” FLEMMING ØRNSKOV, M.D., MPH CHIEF EXECUTIVE OFFICER GALDERMA |
|
Commercial performance
Galderma is on a strong trajectory in 2026 to deliver on another year of opportunities, as it continues to execute on its proven, growth-driven integrated dermatology strategy. Growth for the year is expected to be broad-based across its portfolio, complemented by new launches and geographic expansion.
For the first half of 2026, Galderma achieved net sales of 3,134 million USD, surpassing 3 billion USD for the first time in the first six months of a year. Year-on-year net sales growth was 24.6% at constant currency, predominantly driven by volume and complemented by favorable mix. Excluding the anticipated effects of Nemluvio’s gross-to-net pricing evolution, price contributed positively to growth. Growth remained strong in the second quarter of the year, with net sales up 23.8% year-on-year at constant currency.
Net sales growth remained broad-based, with double-digit growth in most of Galderma’s top 10 markets and across all product categories. Galderma continued to outperform the market in each of its product categories.
View full article here - https://www.aetoswire.com/en/news/2307202656441
View source version on businesswire.com: https://www.businesswire.com/news/home/20260722555754/en/
Contacts
For further information:
Media
Christian Marcoux, M.Sc.
Chief Communications Officer
christian.marcoux@galderma.com
+41 76 315 26 50
Richard Harbinson
Corporate Communications Director
richard.harbinson@galderma.com
+41 76 210 60 62
Investors
Emil Ivanov
Head of Strategy, Investor Relations and ESG
emil.ivanov@galderma.com
+41 21 642 78 12
Jessica Cohen
Investor Relations and Strategy Director
jessica.cohen@galderma.com
+41 21 642 76 43
